This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (81)  • Contact me when this article is cited  Related Content  • Related letters  • Related article  • Similar articles in JAMA  Topic Collections  • Thyroid/ Parathyroid Diseases  • Otolaryngology/ Head & Neck Surgery  • Endocrine Disease of Head & Neck  • Alert me on articles by topic

Louise Davies, MD, MS; H. Gilbert Welch, MD, MPH

JAMA. 2006;295:2164-2167.

Context  Increasing cancer incidence is typically interpreted as an increase in the true occurrence of disease but may also reflect changing pathological criteria or increased diagnostic scrutiny. Changes in the diagnostic approach to thyroid nodules may have resulted in an increase in the apparent incidence of thyroid cancer.

Objective  To examine trends in thyroid cancer incidence, histology, size distribution, and mortality in the United States.

Methods  Retrospective cohort evaluation of patients with thyroid cancer, 1973-2002, using the Surveillance, Epidemiology, and End Results (SEER) program and data on thyroid cancer mortality from the National Vital Statistics System.

Main Outcome Measures  Thyroid cancer incidence, histology, size distribution, and mortality.

Results  The incidence of thyroid cancer increased from 3.6 per 100 000 in 1973 to 8.7 per 100 000 in 2002—a 2.4-fold increase (95% confidence interval [CI], 2.2-2.6; P<.001 for trend). There was no significant change in the incidence of the less common histological types: follicular, medullary, and anaplastic (P>.20 for trend). Virtually the entire increase is attributable to an increase in incidence of papillary thyroid cancer, which increased from 2.7 to 7.7 per 100 000—a 2.9-fold increase (95% CI, 2.6-3.2; P<.001 for trend). Between 1988 (the first year SEER collected data on tumor size) and 2002, 49% (95% CI, 47%-51%) of the increase consisted of cancers measuring 1 cm or smaller; 87% (95% CI, 85%-89%) consisted of cancers measuring 2 cm or smaller. Mortality from thyroid cancer was stable between 1973 and 2002 (approximately 0.5 deaths per 100 000).

Conclusions  The increasing incidence of thyroid cancer in the United States is predominantly due to the increased detection of small papillary cancers. These trends, combined with the known existence of a substantial reservoir of subclinical cancer and stable overall mortality, suggest that increasing incidence reflects increased detection of subclinical disease, not an increase in the true occurrence of thyroid cancer.

Author Affiliations: VA Outcomes Group, Department of Veterans Affairs Medical Center, White River Junction, Vt (Drs Davies and Welch); and Division of Otolaryngology and Department of Community and Family Medicine (Dr Davies) and Center for the Evaluative Clinical Sciences (Dr Welch), Dartmouth Medical School, Hanover, NH.

RELATED LETTERS

Changing Incidence of Thyroid Cancer
Yawei Zhang, Yong Zhu, and Harvey A. Risch
JAMA. 2006;296(11):1350.
EXTRACT | FULL TEXT  

Changing Incidence of Thyroid Cancer—Reply
H. Gilbert Welch and Louise Davies
JAMA. 2006;296(11):1350.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Managing Small Thyroid Cancers
Ernest L. Mazzaferri
JAMA. 2006;295(18):2179-2182.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer
Al-Zahrani et al.
Eur J Endocrinol 2008;158:683-689.
ABSTRACT | FULL TEXT  

The Basis of Racial Differences in the Incidence of Thyroid Cancer
Morris et al.
Ann. Surg. Oncol. 2008;15:1169-1176.
ABSTRACT | FULL TEXT  

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer
Wang et al.
Endocr Relat Cancer 2008;15:183-190.
ABSTRACT | FULL TEXT  

Higher Serum Thyroid Stimulating Hormone Level in Thyroid Nodule Patients Is Associated with Greater Risks of Differentiated Thyroid Cancer and Advanced Tumor Stage
Haymart et al.
J. Clin. Endocrinol. Metab. 2008;93:809-814.
ABSTRACT | FULL TEXT  

The Sea of Uncertainty Surrounding Ductal Carcinoma In Situ--The Price of Screening Mammography
Welch et al.
JNCI J Natl Cancer Inst 2008;100:228-229.
FULL TEXT  

New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy
Riesco-Eizaguirre and Santisteban
Endocr Relat Cancer 2007;14:957-977.
ABSTRACT | FULL TEXT  

BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical Implications
Xing
Endocr. Rev. 2007;28:742-762.
ABSTRACT | FULL TEXT  

Inhibitory Effects of the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 on the Proliferation and Tumor Growth of Thyroid Cancer Cells with BRAF or RAS Mutations
Liu et al.
J. Clin. Endocrinol. Metab. 2007;92:4686-4695.
ABSTRACT | FULL TEXT  

Cost-effective Management of Low-Risk Papillary Thyroid Carcinoma
Shrime et al.
Arch Otolaryngol Head Neck Surg 2007;133:1245-1253.
ABSTRACT | FULL TEXT  

Overstating the Evidence for Lung Cancer Screening: The International Early Lung Cancer Action Program (I-ELCAP) Study
Welch et al.
Arch Intern Med 2007;167:2289-2295.
ABSTRACT | FULL TEXT  

Explaining the increasing incidence of differentiated thyroid cancer
How and Tabah
CMAJ 2007;177:1383-1384.
FULL TEXT  

A Midpoint Assessment of the American Cancer Society Challenge Goal to Decrease Cancer Incidence by 25% Between 1992 and 2015
Sedjo et al.
CA Cancer J Clin 2007;57:326-340.
ABSTRACT | FULL TEXT  

Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis
Rowe et al.
J. Clin. Pathol. 2007;60:1211-1215.
ABSTRACT | FULL TEXT  

The Thyroid Incidentaloma Ignore or Investigate?
Howlett and Speirs
J Ultrasound Med 2007;26:1367-1371.
ABSTRACT | FULL TEXT  

Do All Cancers Need to Be Treated? The Role of Thyroglobulin in the Management of Thyroid Cancer: The 2006 Hayes Martin Lecture
Heller
Arch Otolaryngol Head Neck Surg 2007;133:639-643.
FULL TEXT  

Invited Commentary * Authors' Response
Langer et al.
RadioGraphics 2007;27:861-865.
FULL TEXT  

Staging systems for follicular thyroid carcinoma: application to 171 consecutive patients treated in a tertiary referral centre
Lang et al.
Endocr Relat Cancer 2007;14:29-42.
ABSTRACT | FULL TEXT  

The role of ultrasound in the management of nodular thyroid disease
Jones et al.
Imaging 2007;19:28-38.
ABSTRACT | FULL TEXT  

Papillary Thyroid Cancer and Polymorphic Variants in TSHR- and RET-Related Genes: a Nested Case-Control Study within a Cohort of U.S. Radiologic Technologists
Lonn et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:174-177.
ABSTRACT | FULL TEXT  

Clinical Role of 18F-FDG PET/CT in the Management of Squamous Cell Carcinoma of the Head and Neck and Thyroid Carcinoma
Quon et al.
JNM 2007;48:58S-67S.
ABSTRACT | FULL TEXT  

Cancer Statistics, Trends, and Multiple Primary Cancer Analyses from the Surveillance, Epidemiology, and End Results (SEER) Program
Hayat et al.
The Oncologist 2007;12:20-37.
ABSTRACT | FULL TEXT  

Predicting thyroid malignancy.
Ross
J. Clin. Endocrinol. Metab. 2006;91:4253-4255.
FULL TEXT  

Changing incidence of thyroid cancer.
Zhang et al.
JAMA 2006;296:1350-1350.
FULL TEXT  

What's new in the other general journals.
Tonks and Ravichandran
BMJ 2006;332:1205-1206.
FULL TEXT  

Managing small thyroid cancers.
Mazzaferri
JAMA 2006;295:2179-2182.
FULL TEXT